- Home
- NPCT vs OBIO Comparison
NPCT vs OBIO Comparison
Compare NPCT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- OBIO
- Stock Information
- Founded
- NPCT 2020
- OBIO 2017
- Country
- NPCT United States
- OBIO United States
- Employees
- NPCT N/A
- OBIO N/A
- Industry
- NPCT Investment Managers
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- NPCT Finance
- OBIO Health Care
- Exchange
- NPCT Nasdaq
- OBIO Nasdaq
- Market Cap
- NPCT 316.6M
- OBIO 118.8M
- IPO Year
- NPCT N/A
- OBIO N/A
- Fundamental
- Price
- NPCT $10.98
- OBIO $2.92
- Analyst Decision
- NPCT
- OBIO Strong Buy
- Analyst Count
- NPCT 0
- OBIO 5
- Target Price
- NPCT N/A
- OBIO $14.20
- AVG Volume (30 Days)
- NPCT 107.1K
- OBIO 365.7K
- Earning Date
- NPCT 01-01-0001
- OBIO 08-11-2025
- Dividend Yield
- NPCT 9.82%
- OBIO N/A
- EPS Growth
- NPCT N/A
- OBIO N/A
- EPS
- NPCT N/A
- OBIO N/A
- Revenue
- NPCT N/A
- OBIO $2,886,000.00
- Revenue This Year
- NPCT N/A
- OBIO $20.47
- Revenue Next Year
- NPCT N/A
- OBIO $11.45
- P/E Ratio
- NPCT N/A
- OBIO N/A
- Revenue Growth
- NPCT N/A
- OBIO 30.23
- 52 Week Low
- NPCT $8.58
- OBIO $2.37
- 52 Week High
- NPCT $10.63
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- NPCT 50.48
- OBIO 51.99
- Support Level
- NPCT $11.13
- OBIO $2.89
- Resistance Level
- NPCT $11.29
- OBIO $3.08
- Average True Range (ATR)
- NPCT 0.12
- OBIO 0.20
- MACD
- NPCT -0.02
- OBIO 0.01
- Stochastic Oscillator
- NPCT 19.51
- OBIO 62.86
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.